Modulating effect of Liv.100, an ayurvedic formulation on antituberculosis drug-induced alterations in rat liver microsomes.
The influence of Liv.100 on the hepatotoxicity of antituberculosis drugs [isoniazid (INH), rifampicin (RMP) pyrazinamide (PZA)] was studied in male albino rats. INH, RMP, and PZA were proved to be the most hepatotoxic. Rats were treated with antituberculosis drugs daily for a period of 6 weeks by intragastric administration. The combined use of antituberculosis drugs elevated the levels of cytochrome P-450 and cytochrome-b5. A significant increase was observed in the levels of NADPH-cytochrome P-450 reductase and NADH-cytochrome-b5 reductases after antitubercular drug administration. During antitubercular drug treatment a significant decrease was also observed in the activity of glucose-6-phosphatase. The extent of NADPH-induced and ascorbic acid-induced lipid peroxides were marked in antitubercular drug treatment, when compared with normal control animals. Oral Liv.100 co-administration, for the same period, modulated the alterations in the xenobiotic metabolizing system and microsomal lipid peroxidation in experimental animals. The results are discussed with reference to drug metabolizing enzymes, lipid peroxidation and the hepatoprotective nature of Liv.100.
Saraswathy
S D
SD
Department of Biochemistry and Molecular Biology, University of Madras, Guindy Campus, Chennai - 600 025, India.
Shyamala Devi
C S
CS
D000818:Animals; D000995:Antitubercular Agents / Q000633:toxicity*; D001205:Ascorbic Acid / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D003579:Cytochrome Reductases / Q000187:drug effects; D003573:Cytochrome b Group / Q000187:drug effects; D042966:Cytochrome-B(5) Reductase; D004347:Drug Interactions; D005952:Glucose-6-Phosphatase / Q000187:drug effects; D029001:Herbal Medicine; D007194:India; D007538:Isoniazid / Q000633:toxicity; D015227:Lipid Peroxidation / Q000187:drug effects; D019684:Magnoliopsida; D008297:Male; D008515:Medicine, Ayurvedic; D008862:Microsomes, Liver / Q000187:drug effects*; D009251:NADPH-Ferrihemoprotein Reductase / Q000187:drug effects; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D010946:Plants, Medicinal; D020011:Protective Agents / Q000494:pharmacology; D011718:Pyrazinamide / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000633:toxicity
D000995:Antitubercular Agents; D003573:Cytochrome b Group; C442857:Liv 100; D010936:Plant Extracts; D020011:Protective Agents; D011718:Pyrazinamide; D003577:Cytochrome P-450 Enzyme System; D003579:Cytochrome Reductases; D042966:Cytochrome-B(5) Reductase; D009251:NADPH-Ferrihemoprotein Reductase; D005952:Glucose-6-Phosphatase; D001205:Ascorbic Acid; D007538:Isoniazid; D012293:Rifampin